Actos Patients: The One Year Mark & Cumulative Exposure
Type 2 diabetes patients should be aware that the U.S. Food and Drug Administration (FDA) has warned that the use of Actos (pioglitazone), a prominent diabetes medication, for longer than one year has been linked to a notably increased risk of bladder cancer. In fact, although the one year mark is important, the FDA has also noted that the correlation between treatment and cancer risk is perhaps more closely tied to cumulative pioglitazone exposure. As the one year mark approaches, cumulative exposure for most patients tends to near a kind of tipping point in which bladder cancer risk dramatically rises.
Are you ready to find out more about the risks of bladder cancer and Actos (pioglitazone), one of its possible causes? This isn’t simply a medical issue for some patients, but a legal issue, too. Find out what your first steps need to be by contacting the attorneys and professionals at the law firm of Fears Nachawati today. For your free consultation, call us at 1.866.545.8364 or email email@example.com.